Skip to navigation Skip to content



Professor Catherine Lubetzki, Leader in Myelin Repair Research, Wins Charcot Award

July 22, 2019

Professor Catherine Lubetzki, a clinician-scientist who is a leader in myelin repair research and efforts to stop MS progression, has been selected to receive the prestigious Charcot Award.  The Charcot Award recognizes lifetime achievement in MS research and it is given once every two years by the MS International Federation (MSIF). Prof. Lubetzki is the first woman to receive this award.

She is professor of Neurology at the Sorbonne University in Paris and head of the department of neurological diseases in Salpêtrière Hospital. Prof. Lubetzki coordinates the Salpêtrière MS clinical research center. She was the first woman in France to lead a neurology department.
Prof. Lubetzki’s research is focused on the mechanisms involved in the formation and repair of nerve fiber-insulating myelin, which is a target of immune attacks in MS. Her work focuses on developing strategies to stimulate myelin repair, prevent myelin and nerve fiber damage, and limiting the progression of disability in people with MS.

Prof. Lubetzki has authored more than 250 publications and led, served on, and founded national and international scientific and funding boards and committees. She is a member of the International Progressive MS Alliance Scientific Steering Committee, a founding member of the French Brain Council, and is on the Executive Committee for ECTRIMS, The European Committee for Treatment and Research in Multiple Sclerosis. She serves on the Executive Committee of MSIF’s International Medical and Scientific Board, the Medical and Scientific Board of the French MS Association for Research, and works closely with Ligue française contre la sclérose en plaques (the French association for people with MS).

Read more about Professor Lubetzki and the Charcot Award

About Multiple Sclerosis

Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.